Adjuvant-dependent immune response to malarial transmission-blocking vaccine candidate antigens [published erratum appears in J Exp Med 1993 Feb 1;177(2):following 576] by unknown
BriefDefinitive Report
Adjuvant-dependent Immune Response to Malarial
Transmission-blocking Vaccine Candidate Antigens
By D. J. Rawlings and D. C. Kaslow
From the Molecular Vaccine Section, Laboratory ofMalaria Research, National Institute ofAllergy
and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
Summary
Immune responses in major histocompatibility complex (MHC)-disparate congenic mouse strains
immunized with sexual stage malaria parasites or purified recombinant protein were adjuvant
dependent. Whereas mice exhibited a limited antibody response to immunization with newly
emerged Plasmodium falciparum gametes in Freund's adjuvant, all five congenic mouse strains
responded to several transmission-blocking vaccine candidate antigens, when parasites were emulsified
in a monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) adjuvant. The humoral
response in those animals immunized with the antigen in a MPL/TDM adjuvant was helper
T cell dependent, as evident by boosting of the antibody response after a second immunization.
If the immunogen consisted of purified recombinant protein, then the immune response was
not MHC class II limited in mice immunized with either complete Freund's adjuvant or
TDM/MPL. The potential role ofadjuvants in overcoming apparent immune nonresponsiveness
and the implications for development of a malaria transmission-blocking vaccine are discussed.
T imited immunological recognition of vaccine candidate
j~ antigens may be a major obstacle in the development
of a subunit vaccine against malaria. Limited humoral im-
mune responses to the major candidate antigens from all stages
ofthe parasite life cyclehave been observed in MHC-disparate
congenic animals as well as in humanpopulations in malaria-
endemic regions. These observations have included responses
to: (a) the predominant sporozoite surface protein, the cir-
cumsporozoite protein (CSP) (1-5); (b) protective blood stage
antigens, including the ring-infected erythrocyte surface an-
tigen (RESA) (6, 7) and the major merozoite surface protein
(MSP-1) (8); and (c) the sexual stage target antigens of trans-
mission-blocking antibodies, Pfs230 and Pfs48/45 (9-12).
These data are consistent with the hypothesis that host im-
mune pressure has selected for parasites having a paucity of
helper T cell epitopes within these molecules. Consequently,
the malaria parasite now elicits a limited antibody response
to these antigens (9, 11).
Good et al. (9) found that among six MHC-disparate con-
genic mouse strains immunized with Plasmodium falciparum
gametes, only two strains recognized Pfs48/45 and two
different strains recognized Pfs230. A single strain produced
antibodies capable of immunoprecipitating a previously un-
characterized 40-kD surface radioiodinated gamete protein
(9), Pfs40 (13). The poor immunogenicity ofPfs40 was similar
to that of the other two known transmission-blocking im-
munity target surface antigens, Pfs230 and Pfs48/45, sug-
gesting that Pfs40 might represent an additional target an-
tigen of transmission-blocking antibodies (14, 15). The gene
encoding Pfs40 was recently cloned, and recombinant Pfs40
protein (rPfs40) purified from bacteria (13). We evaluated the
immune responses in five congenic mouse strains to native
and rPfA0, and native Pfs230 and Pfs48/45, using a mono-
phosphoryl lipid A (MPL) and trehalose dimycolate (TDM)
adjuvant in parallel with CFA and IFA. The results of these
studies challenge the current notion ofwhy there is a limited
immune response to malarial vaccine candidate antigens.
Materials and Methods
Parasites.
￿
Mature P falciparum gametocytes of clone 3D7 (16)
were obtained by in vitroculture as previouslydescribed (17) . After
induction ofgametogenesis and exflagellation (18), gametes/zygotes
were purified using a discontinuous Nycodenz gradient (19) and
frozen in aliquots at -70°C.
Recombinant Protein Production.
￿
Recombinant Pfs40 (amino acids
27-374, i.e., without the putative secretory signal sequence) was
expressed in the prokaryotic expressionvector pIH902 (a gift from
Dr. P. Riggs, New England Biolabs, Beverly, MA) as a fusion pro-
tein with maltose binding protein (MBP), purified, and cleaved with
factor Xa as previously described (13).
Immunizations.
￿
Five MHC-disparate congenic mouse strains of
the B10 genetic background (kindly provided by Dr. R. Schwartz,
LCMI, MAID, Bethesda, MD) were used for immunization studies.
One group of animals received an intraperitoneal injection of 100
Ftg of factor Xa-cleaved rPfs40 (or MBP) emulsified in CFA, and
were boosted with antigen in IFA 21 d after the primary injection .
Immune sera were collected 31 d after the primary immunization.
A second groupofcongenic animals was immunized with a pri-
mary intraperitoneal injection of 5 x 106 P. falciparum-purified
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CFA/IFA or in a final volume of 200 P,1 PBS containing 50 lAg
each ofMPL and TDM, 4 F,1 squalene oil, and 0.02% Tween-80
(MPL/TDM adjuvant, R-700 ; Ribi Immunochem, Hamilton,
MT) . These animals received two subsequent injections of 5 x
106 gametes/zygotes in IFA or MPL/TDM adjuvant, respectively,
at 21 and 31 d after the primary injection . Control animals received
primary and subsequent injections of PBS alone in CFA, or
MPL/TDM. Immune sera were collected 28 and 41 d after the
primary immunization .
An additional group ofcongenic animals received aprimary in-
traperitoneal injection of 5 x 106 P . falciparum gametes in
MPL/TDM adjuvant and an identical injection after 10 wk . To
evaluate boosting of the immune response to antigen emulsified
in MPL/TDM adjuvant, immune sera were collected 7d after the
primary, and 1 dbefore and 7 d after the secondaryimmunization .
Immunological Studies.
￿
Surface radioiodination of live parasites
and immunoprecipitation and SDS-PAGE of SDS/Triton X-100-
solubilized gametes ofP . falciparum were performed as described
(9). Rabbit 129 sera and Western blot analysis of rPfs40 (13) and
mAb IIC5B10 (20) were generated andused as previously described.
Results and Discussion
Helper TCell Epitopes in RecombinantPfs40Are Recognized
by All Congenic Mouse Strains. Theimmune response to Pfs40
in sixcongenic mouse strains immunized with unfractionated
total P . falciparum gamete antigens emulsified in CFA was
limited to one strain expressing a single MHC class II allele
(9) . Production of purified rPfs40 has now allowed us to
specifically evaluate the immune response to this protein in
the absence of other parasite molecules that might influence
immunogenicity of PfOO . rPfs40, expressed as MBP-Pfs40
fusion protein without the putative signal peptide, was
purified after factor X, cleavage. Five MHC-disparate con-
genic mouse strains were immunized with rPfs40 emulsified
in CFA and boosted once with rPfs40 in IFA . Surprisingly,
all five strains produced antibodies recognizing the recom-
binant protein by immunoblot (Fig. 1) . Upon subsequent
immunization, all five strains showed a boost in antibody
response by immunoblot (data not shown), indicating that
theimmune response was helperT cell dependent rather than
T cell independent . Sera from mice immunized with MBP
alone immunoblotted only the MBP portion of the fusion
protein (Fig. 1) .
The Limited Immune Response to Native Pfs40 Is Adjuvant
Dependent . TheMHCclass II-independent immune response
to rPfs40 in congenic mice is in sharp contrast to theMHC
class II-dependent response to the native Pfs40 presented in
the complex mixture of antigens present in whole gametes .
Incomplete cleavage ofthe fusion proteinand subsequent con-
tribution of helper T cell epitopes from the MBP portion
of the fusion protein would be a trivial explanation for this
difference. This explanation is unlikely, however, because there
was no evidence ofuncleaved fusion proteinby immunoblot-
ting or protein staining (data not shown) . An alternate ex-
planation is that an immunogen of whole gametes contains
a mixtureof gamete proteins, carbohydrates, lipids, and mem-
brane structures, one or some of which limit the immune
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Figure 1 .
￿
Immunogenicity ofrecombinant Pfs40 emulsified in Freund's
adjuvant and -injected into five congenic mouse strains. Immune sera from
congenic mouse strains (B10.BR, B10.D2, B10.A[3], B10.S[7R], B10.S[9R])
immunized with either affinity-purified maltose binding protein (MBP ;
lanesA) or with rPfs40 partially purified from factor X,-cleaved, affinity-
purified MBP-rPfs40 fusion protein (lanes B) were assayed by immunoblot
analysis of factor X,-cleaved, affinity-purified MBP-rPfs40 fusion protein
size fractionated by SDS-PAGE under nonreducing conditions and elec-
troblotted to nitrocellulose . Although no intact MBP-rPfs40 fusion pro-
tein was detectable by Western blot, the partially purified preparations
ofrPfs40 contained some MBP, and elicited anti-MBP antibodies in some
mouse strains (e.g., B10.A[3R]) . The solid line indicates the location of
rPfs40 on the nitrocellulose blot, and the arrowhead indicates thelocation
of MBP .
response to Pfs40 when presented in a specific adjuvant . To
examine this possibility, we evaluated the effect of adjuvant
onMHC controlofantibody response andantigen specificity
in congenic mice immunized with whole gametes.
MPL, anontoxic LPS derivative of Gram-negative bacterial
endotoxin (21), and trehalose dimycolate, a component of
mycobacterial cell walls (22), have been shown to increase
antibody response to a variety of antigens, including malarial
proteins (23, 24) . The combination of MPL and TDM is
a particularly potent immunological adjuvant (25, 26). There-
fore, the immune response in congenic miceimmunizedwith
P . falciparum gametes emulsified in MPL/TDM was evalu-
ated in parallel with that elicited by gametes emulsified in
CFA. Theresponse using CFA was dramatically limited (Fig.
2 A) . This limited response to immunization with newly
emerged, untransformedP . falciparum gametes, emulsified in
CFA, was similar but not identical to the results noted by
Good et al . (9), using 5-h-old zygotes. The inconsistencies
between our findings and those of Good et al . (9) probably
represent minor differences in experimental design . In marked
contrast to the mice immunizedwith gametes in CFA, when
immunized with gametes in MPL/TDM, all five congenic
mouse strains, independent ofMHC class II alleles expressed,
developed antibodies capable of immunoprecipitating Pfs40and
Pfs48/45 (Figs . 2A and 3) . Only a single strain, B10.S(9R),
immunoprecipitated Pfs230 (Fig . 3) .
Adjuvant-dependent Immune Response to Transmission-blocking AntigensImmunization with Gametes in MPL/TDM Elicits T Cell-
dependent Antibody Responses. Noncognate (T cell-indepen-
dent) help, perhaps mediated by IL2, is one effect an adju-
vant may have on theimmune response to overcome genetic
nonresponsiveness to an immunogen (for example, see refer-
ences 27 and 28) . Such aT cell-independent immune response
would not be expected to elicit a secondary immune response
Figure 3.
￿
Immunoprecipitation of P . fakiparum 1251-labeled surface pro-
teins by immune sera from congenic mouse strains immunized with ga-
metes and zygotes emulsified inMPL/TDM . Two animals ofeach of five
congenic mouse strains (B10.BR,MOM, B10.A[3], B10.S[7R], B10.S[9R])
were immunized andboosted with P .fakiparum gametes and zygotes using
TDM/MPL adjuvant . Serum from each ofthese individual animals (lanes 1
and 2) and from an animal immunized with adjuvant alone (NMS) were
used in immunoprecipitations of SDS/Triton X-100 extracts ofsurface ra-
dioiodinated P . fakiparum gametes and zygotes . Bound 1251-labeled sur-
face proteins and total 1251-labeled extract (Antigen) were size-fractionated
by SDS-PAGE . An autoradiograph ofthe dried gel shown is from an over-
night exposure. Location of target proteins Pfs230 (230), Pfs48/45 (48,
45), and Pfs40 (40) are indicated .
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Figure 2 . (A) Immunoprecipitation of 1251-labeled
Pfs48/45 and pfs40 surface proteins by preimmune (lanes
2 and 4) or immune sera (lanes 1 and 3) from five con-
genic mouse strains immunized with gametes and zygotes
emulsified inMPL/TDM (lanes 1 and 2) or in CFA (lanes
3 and 4), using methods described in Fig. 1. Also shown
are immunoprecipitations withmAb recognizing Pfs48/45
(IIC5B10), rabbit polyclonal sera (129) (reference 34) recog-
nizing Pfs48/45 and M40, and normal mouse sera (NMS) .
' Autoradiograph is from a 3-d exposure rather than over-
night. (B) Immunoprecipitation of 1251-labeled Pfs48/45
and Pfs40 surface proteins by immune sera 7 d after a pri-
mary immunization (lanes 1), or 1 d before (lanes 2) or
7 d after (lane 3) a secondary immunization with gametes
and zygotes emulsified in MPL/TDM .
on subsequent immunizations. Therefore, to evaluate whether
subsequent immunizations elicit a secondary antibody response
to these gamete proteins, sera were collected after primary
and secondary immunizations ofadditional animals ofall five
congenic mouse strains immunized withP .fkiparum gametes
in MPL/TDM adjuvant . Immunoprecipitations with these
sera clearly demonstrated a boost of antibody response to Pfs40
and Pfs48/45 in all of the congenic mouse strains (Fig. 2 B) .
Little or no detectable antibody response to Pfs40 and Pfs48/45
was present in primary immune sera or in sera immediately
before the secondary immunization . Both proteins were im-
munoprecipitated, however, by sera obtained 7 d after the
secondary immunization given 10 wk later. Nonspecific poly-
clonal B cell stimulation by MPL/TDM adjuvant is unlikely
to explain this universal response. Rather, these data suggest
that the antibody response elicited byP. falciparum gametes
in the adjuvant is T cell dependent .
Implicationsfor Vaccine Development .
￿
These immunogenicity
studies producedtwo unexpected results. First, the immunore-
stricted antibody response in MHC-disparate congenic animals,
immunized with P .falciparum gametes, was adjuvant depen-
dent and not necessarily due to an absence of helper T cell
epitopes . When CFA was used, we confirmed the apparent
MHC class II-associated nonresponsiveness to the surface pro-
teins, Pfs40 and Pfs48/45 . In contrast, though, to previous
studies, we observed an MHC class II-independent but T
cell-dependent immune response to the same proteins using
MPL/TDM adjuvant . Second, unlike the response to Pfs40
in the milieu ofwhole gametes emulsified in CFA, the anti-
body response to purified, recombinant Pfs40 in CFA was
not class II MHC dependent .
The divergent immune responses to whole gametes
emulsified in different adjuvants may result from alterations
in antigen processing/presentation and/or elimination of im-
mune suppression . For instance, TDM/MPL adjuvant may
allow the presentation of additional helper T cell epitopes
by macrophages and other APC, mediated through changes
in antigen processing or presentation pathways that do not
occur with CFA . Both MPL (25) and TDM (29) activate
macrophages and stimulate cytokine production . This acti-vation may fundamentally alter antigen processing. Addition-
ally, chemical and conformational changes that may occur
when an antigen is emulsified in different adjuvants may alter
specific sites of antigen proteolytic processing and, therefore,
alter antigen presentation.
Alternatively, it is possible that the MPL/TDM adjuvant
interferes with specific suppressor T cell proliferation, allowing
expression of previously suppressed T cell-dependent anti-
body responses. For example, MPL specifically inactivates sup-
pressor T cells but appears to have little effect on helper T
cell activity (30). Notably, MPL overcomes low-dose immuno-
logical paralysis and potentiates the immune response to type
III pneumococcal polysaccharide by eliminating inhibitory
effects of suppressor T cells (31). In the case ofP. falciparum
sexual stage antigens, any adjuvant-dependent immunosup-
pressive model must be antigen specific to account for adjuvant-
independent widespread immunogenicity of two other sexual
stage proteins, Pfs25 and Pfg27/25, in congenic mouse strains
(9) and in humans (11), respectively. Furthermore, the MHC
class II-independent immune response to rPfs40 alone, and
the contrasting limited response to the native molecule in
immunization studies with whole gametes (using identical
adjuvant systems), suggests that a suppressor determinant(s),
if involved, is in an unrelated molecule(s). Therefore, unlike
CFA, MPL/TDM adjuvant may be capable of overcoming
an antigen-specific suppressor response in animals immunized
with total gametes that remains present when CFA is used.
A similar situation, that is, the presence of a suppressor de-
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